<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="117720">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01980069</url>
  </required_header>
  <id_info>
    <org_study_id>4-2013-0451</org_study_id>
    <nct_id>NCT01980069</nct_id>
  </id_info>
  <brief_title>A Double-blind, Randomized, Parallel Design Study to Compare the Effectiveness of Sugammadex Versus Neostigmine in Improving Surgical Condition in Subjects Undergoing Laryngeal Microsurgery</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yonsei University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Yonsei University</source>
  <oversight_info>
    <authority>Korea: Institutional Review Board (Severance Hospital)</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Investigators hypothesized that the surgical condition will be improved with the use of
      sugammadex in patients undergoing laryngeal microsurgery. Investigators will compare the
      effect of sugammadex and neostigmine on the surgical condition during laryngeal
      microsurgery.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2013</start_date>
  <completion_date type="Anticipated">November 2014</completion_date>
  <primary_completion_date type="Anticipated">November 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>surgical condition</measure>
    <time_frame>up to 1 hour after the end of surgery</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Primary outcome is the proportion of patients who have clinically acceptable surgical condition. The surgeon will evaluate the surgical condition as a surgical rating scale during surgery (extremely poor condition, poor condition, acceptable condition, good condition, optimal condition).</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">92</enrollment>
  <condition>General Anesthesia</condition>
  <arm_group>
    <arm_group_label>Neostigmine arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Neostigmine arm</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sugammadex arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Sugammadex arm</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sugammadex</intervention_name>
    <description>In sugammadex group, sugammadex (Bridion, Merck Shart and Dohme (MSD), Oss, the Netherlands) will be administered intravenously in different doses according to the degree of muscle relaxation. Sugammadex 8 mg/kg will be administered if there is no response on post-tetanic count (PTC) stimulus. Sugammadex 4 mg/kg will be administered if PTC is more than 1 or 2. Sugammadex 2 mg/kg will be administered if T2 response appears on train-of-four (TOF)  stimulus.</description>
    <arm_group_label>Sugammadex arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Neostigmine</intervention_name>
    <description>In neostigmine group, neostigmine 50 ㎍/kg will be administered intravenously with glycopyrrolate 10 ㎍/kg when the T2 response appears on TOF stimuli.</description>
    <arm_group_label>Neostigmine arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  adult patients of age over 20 years

          -  scheduled for laryngeal microsurgery under general anesthesia

        Exclusion Criteria:

          -  anticipated difficult intubation, cervical spine disease, neuromuscular disease,
             acute or chronic renal failure, liver cirrhosis or liver failure

          -  history of allergy to nondepolarizing muscle relaxant

          -  history of malignant hyperthermia

          -  pregnant woman

          -  body mass index over 35 kg/m2
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Young Chul Yoo, MD</last_name>
    <phone>82-2-2227-4643</phone>
    <email>seaoyster@yuhs.ac</email>
  </overall_contact>
  <location>
    <facility>
      <name>Severance Hospital</name>
      <address>
        <city>Seoul</city>
        <state>Seodaemun-gu</state>
        <zip>120-752</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Young Chul Yoo, MD</last_name>
      <phone>82-2-2227-4643</phone>
      <email>seaoyster@yuhs.ac</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>November 2013</verification_date>
  <lastchanged_date>April 3, 2014</lastchanged_date>
  <firstreceived_date>November 1, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Sugammadex</keyword>
  <keyword>Neostigmine</keyword>
  <keyword>Surgery</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Neostigmine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
